beta-Thromboglobulin
A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders.
Platelet Factor 4
A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.
Beta-Globulins
Encyclopedias as Topic
Blood Platelets
Platelet Activation
Fibrinopeptide A
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Platelet Membrane Glycoproteins
Platelet Adhesiveness
Platelet Aggregation
Hypertension, Pulmonary
Endarterectomy
Pulmonary Artery
Thromboembolism
Estradiol
Administration, Cutaneous
Transdermal Patch
Drug Interactions
Product Labeling
Health Resources
Aspirin
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Consent Forms
Documents describing a medical treatment or research project, including proposed procedures, risks, and alternatives, that are to be signed by an individual, or the individual's proxy, to indicate his/her understanding of the document and a willingness to undergo the treatment or to participate in the research.
Renal Dialysis
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Search Engine
Receptors, sigma
A class of cell surface receptors recognized by its pharmacological profile. Sigma receptors were originally considered to be opioid receptors because they bind certain synthetic opioids. However they also interact with a variety of other psychoactive drugs, and their endogenous ligand is not known (although they can react to certain endogenous steroids). Sigma receptors are found in the immune, endocrine, and nervous systems, and in some peripheral tissues.
Genome, Human
Myelin Basic Protein
Antibodies
Haloperidol
A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
PubMed
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
Sleep Apnea Syndromes
Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.
Sleep Apnea, Obstructive
A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
Sleep
Polysomnography
Simultaneous and continuous monitoring of several parameters during sleep to study normal and abnormal sleep. The study includes monitoring of brain waves, to assess sleep stages, and other physiological variables such as breathing, eye movements, and blood oxygen levels which exhibit a disrupted pattern with sleep disturbances.
Hypertension
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
NMR structure and dynamics of monomeric neutrophil-activating peptide 2. (1/247)
Neutrophil-activating peptide 2 (NAP-2), which demonstrates a range of proinflammatory activities, is a 72-residue protein belonging to the alpha-chemokine family. Although NAP-2, like other alpha-chemokines, is known to self-associate into dimers and tetramers, it has been shown that the monomeric form is physiologically active. Here we investigate the solution structure of monomeric NAP-2 by multi-dimensional 1H-NMR and 15N-NMR spectroscopy and computational modelling. The NAP-2 monomer consists of an amphipathic, triple-stranded, anti-parallel beta-sheet on which is folded a C-terminal alpha-helix and an aperiodic N-terminal segment. The backbone fold is essentially the same as that found in other alpha-chemokines. 15N T1, T2 and nuclear Overhauser effects (NOEs) have been measured for backbone NH groups and used in a model free approach to calculate order parameters and conformational exchange terms that map out motions of the backbone. N-terminal residues 1 to 17 and the C-terminus are relatively highly flexible, whereas the beta-sheet domain forms the most motionally restricted part of the fold. Conformational exchange occurring on the millisecond time scale is noted at the top of the C-terminal helix and at proximal residues from beta-strands 1 and 2 and the connecting loop. Dissociation to the monomeric state is apparently responsible for increased internal mobility in NAP-2 compared with dimeric and tetrameric states in other alpha-chemokines. (+info)In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. (2/247)
Thrombin-induced platelet microbicidal protein-1 (tPMP-1) and human neutrophil defensin-1 (HNP-1) are small, cationic antimicrobial peptides. These peptides exert potent in vitro microbicidal activity against a broad spectrum of human pathogens, including Staphylococcus aureus. Evidence suggests that tPMP-1 and HNP-1 target and disrupt the bacterial membrane. However, it is not yet clear whether membrane disruption itself is sufficient to kill the bacterium or whether subsequent, presumably intracellular, events are also involved in killing. We investigated the staphylocidal activities of tPMP-1 and HNP-1 in the presence or absence of pretreatment with antibiotics that differ in their mechanisms of action. The staphylocidal effects of tPMP-1 and HNP-1 on control cells (no antibiotic pretreatment) were rapid and concentration dependent. Pretreatment of S. aureus with either penicillin or vancomycin (bacterial cell wall synthesis inhibitors) significantly enhanced the anti-S. aureus effects of tPMP-1 compared with the effects against the respective control cells over the entire tPMP-1 concentration range tested (P < 0.05). Similarly, S. aureus cells pretreated with these antibiotics were more susceptible to HNP-1 than control cells, although the difference in the effects against cells that received penicillin pretreatment did not reach statistical significance (P < 0.05 for cells that received vancomycin pretreatment versus effects against control cells). Studies with isogenic pairs of strains with normal or deficient autolytic enzyme activities demonstrated that enhancement of S. aureus killing by cationic peptides and cell wall-active agents could not be ascribed to a predominant role of autolytic enzyme activation. Pretreatment of S. aureus cells with tetracycline, a 30S ribosomal subunit inhibitor, significantly decreased the staphylocidal effect of tPMP-1 over a wide peptide concentration range (0.16 to 1.25 microgram/ml) (P < 0.05). Furthermore, pretreatment with novobiocin (an inhibitor of bacterial DNA gyrase subunit B) and with azithromycin, quinupristin, or dalfopristin (50S ribosomal subunit protein synthesis inhibitors) essentially blocked the S. aureus killing resulting from exposure to tPMP-1 or HNP-1 at most concentrations compared with the effects against the respective control cells (P < 0.05 for a tPMP-1 concentration range of 0.31 to 1.25 microgram/ml and for an HNP-1 concentration range of 6.25 to 50 microgram/ml). These findings suggest that tPMP-1 and HNP-1 exert anti-S. aureus activities through mechanisms involving both the cell membrane and intracellular targets. (+info)Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. (3/247)
Polyethylene glycol (PEG)-hirudin is a derivative of hirudin with a long plasma half-life. We have compared the efficacy of PEG-hirudin with unfractionated heparin (UH) in preventing arterial thrombosis. Arterial thrombus formation was induced ex vivo in 12 healthy human volunteers by exposing a tissue factor-coated coverslip positioned in a parallel-plate perfusion chamber to flowing nonanticoagulated human blood drawn directly from an antecubital vein at an arterial wall shear rate of 2600 s-1 for 3.5 minutes. PEG-hirudin, UH, or saline (as control) were administered ex vivo through a heparin-coated mixing device positioned proximal to the perfusion chamber. Platelet and fibrin deposition was quantified by immunoenzymatic measure of the P-selectin and D-dimer content of dissolved plasmin-digested thrombi, respectively. UH was administered to a plasma concentration of 0.35 IU/mL. This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01). UH did not significantly prevent platelet deposition. However, fibrin deposition was reduced by 39% (P<0.05). PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively. In contrast to UH, PEG-hirudin prevented both platelet and fibrin deposition in a dose-dependent manner with a >80% reduction at 5 microg/mL (P<0.01). Furthermore, the plasma level of PEG-hirudin required to significantly prevent fibrin deposition (0.5 microg/mL) corresponded to a much shorter prolongation of activated partial thromboplastin time (48+/-2 seconds) than that needed for UH (79+/-4 seconds). Thus, our results are compatible with the view that thrombin is greatly involved in recruitment of platelets in evolving thrombi, and that PEG-hirudin is an effective agent for preventing arterial thrombosis in a human ex vivo experimental model. (+info)Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. (4/247)
Vascular endothelial growth factor (VEGF) is important for the proliferation, differentiation, and survival of microvascular endothelial cells. It is a potent angiogenic factor and a specific endothelial cell mitogen that increases fenestration and extravasation of plasma macromolecules. Recently, large quantities of VEGF were detected in human megakaryocytes. Incubation of human platelets with thrombin in vitro resulted in the release of large amounts of VEGF. To investigate whether VEGF is released from platelets during coagulation activation in vivo, we measured in human subjects VEGF at the site of plug formation, ie, in blood emerging from a standardized injury made to determine bleeding time (shed blood). VEGF was also determined in the same volunteers after treatment with the specific thrombin inhibitor recombinant hirudin (r-hirudin). In a double-blind, randomized, crossover study, 17 healthy male volunteers (aged 20 to 35 years) were investigated. VEGF concentrations were measured in venous blood and in shed blood by the use of an immunoassay 10 minutes after intravenous administration of r-hirudin (0.35 mg/kg of body weight) or physiological saline. Prothrombin fragment f1.2 (f1.2) and beta-thromboglobulin (beta-TG) were determined as indicators of coagulation and platelet activation, respectively. Concentrations of VEGF, f1.2, and beta-TG in shed blood 4 minutes after injury were significantly higher than in venous blood (VEGF, 55.8+/-9.2 versus <20 pg/mL, P<0.001; f1.2, 71.3+/-10.4 versus 0.78+/-0.03 nmol/L, P<0. 001; beta-TG, 2290+/-170 versus 53.2+/-14.0 ng/mL, P<0.001). Administration of r-hirudin caused a >50% inhibition of the beta-TG and f1.2 levels in shed blood. In a similar manner, much lower amounts of VEGF were detectable at the site of plug formation after r-hirudin treatment (69.0+/-9.5 versus 37.8+/-2.6 pg/mL per minute; P=0.0015). Our data indicate that substantial quantities of VEGF are released from platelets during the interaction with the injured vessel wall in vivo. This finding may be relevant with respect to wound healing and tissue repair, tumor vascularization, or arterial thrombus formation. (+info)Increased formation of thromboxane in vivo in humans with mastocytosis. (5/247)
Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased (>2 SD above the mean) in at least one urine sample from 65% of patients studied. Of these, 91% of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and Ntau-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro-thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation. (+info)Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. (6/247)
OBJECTIVES: This study investigated parameters of endogenous fibrinolysis, activation of coagulation and platelets, and endothelin levels before and after elective percutaneous transluminal coronary angioplasty (PTCA) in patients with stable coronary artery disease (CAD). BACKGROUND: Abrupt vessel closure is a serious short-term complication after PTCA and is often unforeseeable. Detailed insight into the effect of PTCA on hemostasis, platelets and the release of vasoconstrictive substances, which are among the mainly discussed mechanisms of abrupt vessel closure, is needed to enhance the safety of coronary intervention. METHODS: Plasma levels of markers of platelet activity, coagulation, endogenous fibrinolysis and endothelins were determined in 20 patients with stable CAD undergoing elective PTCA. The blood specimens were drawn before, immediately after, 1 h after intervention and on the next morning. RESULTS: All patients showed an initially uncomplicated PTCA. Regarding the efficacy of anticoagulation after receiving 15.000 IU heparin during PTCA, two groups were compared. In eight patients with ineffective anticoagulation production of thrombin and platelet activation directly after and 1 h after PTCA was significantly higher compared with 12 patients with effective anticoagulation. Despite the strong activation of coagulation, only a low fibrinolytic response could be observed. Endothelins rose significantly after PTCA in both groups but stayed longer on higher levels in patients with distinct thrombin generation. Three of the eight patients without sufficient heparin treatment suffered abrupt vessel closure. CONCLUSIONS: Initially uncomplicated dilation of coronary arteries leads to systemically measurable activation of coagulation and platelets in patients with ineffective doses of heparin and release of endothelins in all patients. Therefore, individual adjustment of anticoagulation and platelet inhibition in combination with effective antivasospastic substances are needed in every patient before, during and after initially uncomplicated PTCA to prevent this serious complication. (+info)Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. (7/247)
Thrombin-induced platelet microbicidal protein 1 (tPMP-1) is a small, cationic peptide released from rabbit platelets following thrombin stimulation. In vitro resistance to this peptide among strains of Staphylococcus aureus correlates with the survival advantage of such strains at sites of endothelial damage in humans as well as in experimental endovascular infections. The mechanisms involved in the phenotypic resistance of S. aureus to tPMP-1 are not fully delineated. The plasmid-encoded staphylococcal gene qacA mediates multidrug resistance to multiple organic cations via a proton motive force-dependent efflux pump. We studied whether the qacA gene might also confer resistance to cationic tPMP-1. Staphylococcal plasmids encoding qacA were found to confer resistance to tPMP-1 in an otherwise susceptible parental strain. Deletions which removed the region containing the qacA gene in the S. aureus multiresistance plasmid pSK1 abolished tPMP-1 resistance. Resistance to tPMP-1 in the qacA-bearing strains was inoculum independent but peptide concentration dependent, with the level of resistance decreasing at higher peptide concentrations for a given inoculum. There was no apparent cross-resistance in qacA-bearing strains to other endogenous cationic antimicrobial peptides which are structurally distinct from tPMP-1, including human neutrophil defensin 1, protamine, or the staphylococcal lantibiotics pep5 and nisin. These data demonstrate that the staphylococcal multidrug resistance gene qacA also mediates in vitro resistance to cationic tPMP-1. (+info)PDGF-AB release during and after haemodialysis procedure. (8/247)
BACKGROUND: During haemodialysis blood membrane contact causes the release of the content of platelet alpha-granules, which contain platelet-derived growth factor (PDGF). In view of its possible role in accelerated atherosclerotic processes, we evaluated the intra- and post-dialytic changes in PDGF-AB serum levels during haemodialysis sessions performed using a cellulosic membrane. METHODS: Using the ELISA method, PDGF-AB, platelet factor-4 (PF4) and beta-thromboglobulin (beta-TG) levels were determined in peripheral blood, as well as in arterial and venous haemodialyser lines, in 10 patients each of whom underwent five consecutive dialysis sessions with a CU membrane. Blood samples were taken at 0, 15, 30, 60, 120, 180 and 240 min during dialysis and at 1, 4 and 20 h after the end of the session. In the same group of patients the levels of the same molecules were also determined after a heparin bolus injection of 4500 IU, blood samples were taken at 0, 15 and 30 min after injection of the bolus. RESULTS: PDGF-AB serum levels increased, remained consistently high during the haemodialysis session (in particular +134+/-20% after 30 min, P<0.001, and +140+/-5% after 240 min, P<0.001) and returned to basal values only after 20 h following the end of the session. PF4 and beta-TG showed a similar trend to PDGF. The heparin bolus injection caused only a small increase (+15+/-5% at 30 min) in PDGF-AB serum levels. CONCLUSIONS: PDGF-AB is released during dialysis mainly as consequence of the blood-membrane contact and it returns only slowly to basal values. (+info)
Platelet basic protein | definition of platelet basic protein by Medical dictionary
Beta-thromboglobulin - Wikipedia
Plasma beta-thromboglobulin is correlated with platelet adhesi...
Human bTG ELISA Kit | biobool.com
OpenAIRE | Efeito da imunoterapia sublingual sobre a atividad
Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus |...
Oryctolagus cuniculus platelet microbicidal protein
Summary Report | CureHunter
DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN,...
Survival and recovery of human platelets stored for five days in a non- plasma medium | Blood | American Society of Hematology
Effect of Nephral 400 ST Dialysis Membrane on Coagulation in Hemodialysis - Full Text View - ClinicalTrials.gov
Factor 4 Plaquetar indueix activitat proinflamadora en les cèl·lules Natural Killer Humanes, El
Platelet function after in vivo and in vitro treatment with thrombolytic agents | IRIS UNIPV
MAA370Ra22 | β-血小板球蛋白(bTG)单克隆抗体 | Rattus norvegicus (Rat,大鼠) USCN(武汉优尔生商贸有限公司)
Increases in circulating levels of monocyte-platelet and neutrophil-platelet complexes following hip arthroplasty | Clinical...
Plus it
Reactome | CD36 [platelet alpha granule membrane]
Reactome | LHFPL2 [platelet alpha granule membrane]
Heparin-Binding Peptide III, Stem cell fate regulator (ab142114) | Abcam
ENA 78 Protein Mouse Recombinant | CXCL5 Antigen | ProSpec
Protein Foundry - Recombinant Human CXCL5
CXCL5 - Вікіпедія
Secondary structure of neutrophil-activating peptide-2 determined by 1H-nuclear magnetic resonance spectroscopy | Biochemical...
Atrial fibrillation and the prothrombotic state: revisiting Virchows triad in 2020. | OnMedica
Infection After Acute Ischemic Stroke | Stroke
ENA-78 Rabbit Polyclonal Antibody - Western Blot Antibodies - Bioworld Consulting Laboratories, LLC.
ELISA Kit for Interleukin 8 (IL8), Sandwich ELISA, CLOUD-CLONE CORP.(CCC)
Aging | Aging exacerbates neutrophil pathogenicity in ischemic stroke - Figure
A1BG - Alpha-1B-glycoprotein precursor - Homo sapiens (Human) - A1BG gene & protein
Platelet Factor 4 | Harvard Catalyst Profiles | Harvard Catalyst
LAA080Hu82 | FITC-Linked Monoclonal Antibody to Interleukin 8 (IL8) | Homo sapiens (Human) USCN(Wuhan USCN Business Co., Ltd. )
Recombinant human GRO alpha protein (ab73810) References
Model the dynamics of speed governing system, steam turbine,
and multimass shaft - Simulink
ccl1 Protein, chemokine (C-C motif) ligand 1 - Creative BioMart
AJOU Open Repository: Effects of Cytokine on Platelet Activation
小鼠GRO alpha ELISA试剂盒(CXCL1) | Abcam中国官方网站
小鼠钩端螺旋体IgG(Lebtospira)ELISA试剂盒 中国教育装备采购网
Placement of Multiorificed CVP Catheters Via Antecubital Veins Using Intravascular Electrocardiography | Anesthesiology | ASA...
Neutrophil microbicidal assay | definition of neutrophil microbicidal assay by Medical dictionary
Neutrophil microbicidal assay legal definition of neutrophil microbicidal assay
Platelet Factor 4 (PF4) ELISA Kits
RPA172Mu02 | 血小板因子4(PF4)重组蛋白 | Mus musculus (Mouse,小鼠) USCN(武汉优尔生商贸有限公司)
Gro Berntsen - Ehealthresearch.no (NO)
Sensors | Free Full-Text | NCO-sP(EO-stat-PO) Coatings on Gold Sensors-a QCM Study of Hemocompatibility
Helicobacter pylori Lipopolysaccharide Binds to CD14 and Stimulates Release of Interleukin-8, Epithelial Neutrophil-Activating...
TJH Atlas of Hematology
National Tsing Hua University Institutional Repository:The neutrophil-activating protein of Helicobacter pylori promotes...
Instant ELISA Kit for Interleukin 8 (IL8) | IEA080Ov | Ovis aries; Ovine (Sheep) CLOUD-CLONE CORP.(CCC)
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting - Full Text View - ClinicalTrials.gov
IJMS | Free Full-Text | Inhibitory Effect of Statins on Inflammation-Related Pathways in Human Abdominal Aortic Aneurysm Tissue
GRO gamma抗体(ab10367)| Abcam中国
CXCL7
It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP). It is a protein that is released in large ... Tunnacliffe A, Majumdar S, Yan B, Poncz M (1992). "Genes for beta-thromboglobulin and platelet factor 4 are closely linked and ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ...
CXCL1
... a growth factor structurally related to beta-thromboglobulin". The EMBO Journal. 7 (7): 2025-33. doi:10.1002/j.1460-2075.1988. ... Becker S, Quay J, Koren HS, Haskill JS (March 1994). "Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression ... capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma ...
Renal vein thrombosis
Reduced osmotic pressure will trigger the liver to produce more proteins like fibrinogen and beta-thromboglobulin, which ... Cystathionine beta synthase deficiency, also known as homocystinuria, is an autosomal recessive inherited disorder in which the ...
CXCL7
1992). "A new assay for beta-thromboglobulin in urine.". Thromb. Res. 64 (1): 33-43. PMID 1837963. doi:10.1016/0049-3848(91) ... proinflamatorni citokin (IL-1, TNF-alfa) • Th1 (INF-gama i TNF-beta) • Th2 (IL-4, IL-5, IL-6, IL-10, IL-13) • Th17 (IL-17,IL-22 ... Tunnacliffe A, Majumdar S, Yan B, Poncz M (1992). "Genes for beta-thromboglobulin and platelet factor 4 are closely linked and ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ...
List of MeSH codes (D12.776)
... beta-2 microglobulin MeSH D12.776.377.715.182.160 - beta-thromboglobulin MeSH D12.776.377.715.182.200 - complement factor h ... beta-thromboglobulin MeSH D12.776.467.374.200.100 - chemokines, c MeSH D12.776.467.374.200.110 - chemokines, cc MeSH D12.776. ... beta-crystallin a chain MeSH D12.776.306.366.300.200 - beta-crystallin b chain MeSH D12.776.331.199.750.500 - succinate ... thyroid hormone receptors beta MeSH D12.776.624.664.700.915 - RNA-binding protein FUS MeSH D12.776.624.664.700.957 - stathmin ...
List of MeSH codes (D12.776.124)
... beta-2 microglobulin MeSH D12.776.124.790.223.160 - beta-thromboglobulin MeSH D12.776.124.790.223.200 - complement factor h ...
Platelet factor 4
"Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in ...
List of MeSH codes (D23)
... beta-thromboglobulin MeSH D23.125.300.100 - chemokines, c MeSH D23.125.300.110 - chemokines, cc MeSH D23.125.300.120 - ... beta-thromboglobulin MeSH D23.469.200.100 - chemokines, c MeSH D23.469.200.110 - chemokines, cc MeSH D23.469.200.120 - ... beta subunit, human MeSH D23.101.840.375 - hormones, ectopic MeSH D23.101.840.400 - ki-67 antigen MeSH D23.101.840.500 - ... transforming growth factor beta MeSH D23.348.479.996 - wnt proteins MeSH D23.348.479.996.500 - wnt1 protein MeSH D23.348. ...
List of MeSH codes (D12.644)
... beta-thromboglobulin MeSH D12.644.276.174.200.100 - chemokines, c MeSH D12.644.276.174.200.110 - chemokines, cc MeSH D12.644. ... MeSH D12.644.050.200 - defensins MeSH D12.644.050.200.050 - alpha defensins MeSH D12.644.050.200.075 - beta defensins MeSH ... beta-msh MeSH D12.644.400.460.115 - gamma-msh MeSH D12.644.400.465 - msh release-inhibiting hormone MeSH D12.644.400.470 - msh- ... gtp-binding protein beta subunits MeSH D12.644.360.375.730 - gtp-binding protein gamma subunits MeSH D12.644.360.375.940 - ...
Beta-thromboglobulin
... (also known as β-thromboglobulin) is a protein that is stored in alpha-granules of platelets and released ... Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. Levels of Beta- ... Cytokines & Cells Online Pathfinder Encyclopaedia --> Beta-Thromboglobulin Retrieved on August 17, 2009 Pillai MM, Iwata M, ... Thromboglobulin is used to index platelet activation. It is measured by ELISA in blood plasma or urine, and often in ...
Index of biochemistry articles
... beta adrenergic receptor - beta sheet - beta-1 adrenergic receptor - beta-2 adrenergic receptor - beta-thromboglobulin - ... transforming growth factor beta - transforming growth factor beta receptor - transient receptor potential - translation ( ... alpha-beta T-cell antigen receptor - alpha-fetoprotein - alpha-globulin - alpha-macroglobulin - alpha-MSH - Ames test - amide ... interferon-beta - interleukin receptor - interleukin-1 receptor - interleukin-2 receptor - interleukin-3 - interleukin-3 ...
Platelet
The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 (PLCB2), resulting in inositol 1,4,5- ... B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII δ granules (delta or dense granules) - containing ADP or ... Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the ...
Platelet
The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 PLCB2, resulting in inositol 1,4,5- ... B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII. ... Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the ...
Beta-thromboglobulin - Wikipedia
Beta-thromboglobulin (also known as β-thromboglobulin) is a protein that is stored in alpha-granules of platelets and released ... Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. Levels of Beta- ... Cytokines & Cells Online Pathfinder Encyclopaedia Beta-Thromboglobulin Retrieved on August 17, 2009 Pillai MM, Iwata M, ... Thromboglobulin is used to index platelet activation. It is measured by ELISA in blood plasma or urine, and often in ...
DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN,...
DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ... DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ... DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ...
beta-Thromboglobulin | Profiles RNS
... "beta-Thromboglobulin" by people in this website by year, and whether "beta-Thromboglobulin" was a major or minor topic of these ... Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of ... "beta-Thromboglobulin" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "beta-Thromboglobulin" by people in Profiles. ...
Plasma beta-thromboglobulin is correlated with platelet adhesi...
Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus ... Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus. ... We measured simultaneous plasma beta-thromboglobulin (BTG) and adhesion of 51Cr-labelled, washed platelets to confluent, bovine ...
Mouse bTG(Beta-Thromboglobulin) ELISA Kit - Bio EMM
Mouse bTG(Beta-Thromboglobulin) ELISA Kit. Mouse bTG(Beta-Thromboglobulin) ELISA Kit ... It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP).Beta-thromboglobulin (?-TG) has a molecular ... It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP).Beta-thromboglobulin (?-TG) has a molecular ... It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP).Beta-thromboglobulin (?-TG) has a molecular ...
Human bTG(Beta-Thromboglobulin) ELISA Kit - Dla Różnorodności Biologicznej - Life Sciences
Human bTG(Beta-Thromboglobulin) ELISA Kit. Human bTG(Beta-Thromboglobulin) ELISA Kit. To Order Contact us: [email protected] ... Should the Mouse Beta-Thromboglobulin (bTG) ELISA Kit is proven to show malperformance, you will receive a refund or a free ... Should the Mouse Beta-Thromboglobulin (bTG) ELISA Kit is proven to show malperformance, you will receive a refund or a free ... Should the Rat Beta-Thromboglobulin (bTG) ELISA Kit is proven to show malperformance, you will receive a refund or a free ...
BTG anti-proliferation factor 1 ELISA Kits | Biocompare.com
NDLI: Protease action and generation of beta-thromboglobulin-like protein followed by platelet activation
... of beta-thromboglobulin-like protein followed by platelet activation Protease action and generation of beta-thromboglobulin- ... beta-Thromboglobulin (betaTG) is a platelet specific protein present in the a-granules and secreted into the surrounding medium ... protein is released from alpha-granules and is broken down into smaller fragments after release to form beta-thromboglobulin ( ... beta-aminoethyl ether)N,N-tetra acetic acid (EGTA) showed disappearance of an 8.0-kDa band. In the absence of the cation ...
C t T C G X p a ??W
Pulmonary hypertension associated with long-standing thrombocytosis
Gilbert C. White, II, PhD | Professor | Medical College of Wisconsin
Estraderm - FDA prescribing information, side effects and uses
Esclim (Estradiol Transdermal): Uses, Dosage, Side Effects, Interactions, Warning
NDL India: A Biochemical Study on the Effect of Proteolysis of Beta-Thromboglobulin Proteins Released from Activated Platelets...
Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study - Full Text View - ClinicalTrials.gov
DailyMed - LYLLANA- estradiol patch, extended release
C-X-C motif chemokine 7 | definition of C-X-C motif chemokine 7 by Medical dictionary
The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and...
Platelet function and exercise-induced myocardial ischaemia in coronary heart disease patients.
Recombinant Human IL-8 protein (ab167998) | Abcam
PPBP Gene - GeneCards | CXCL7 Protein | CXCL7 Antibody
Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4. (PMID: 1826003) ... Novel C-terminally truncated isoforms of the CXC chemokine beta- thromboglobulin and their impact on neutrophil functions. ( ... Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along ... connective tissue activating peptide III,including platelet basic protein,precursor of beta thromboglobulin and neutrophil ...
Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. - PubMed - NCBI
CXCL7/NAP-2 Antibody (MM0218-9H20) [Alexa Fluor® 700] (NBP2-12233AF700): Novus Biologicals
CXCL7 - Wikipedia
It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP). It is a protein that is released in large ... Tunnacliffe A, Majumdar S, Yan B, Poncz M (1992). "Genes for beta-thromboglobulin and platelet factor 4 are closely linked and ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ...
Dissociation of thrombin generation and platelet secretion in diabetes mellitus. | CureHunter
Platelet Function Changes in Acute Myocardial Infarction | SpringerLink
Macrophage Inflammatory Proteins (MIPs) - Growth Factors and Cytokines | Sigma-Aldrich
This family also includes platelet factor 4 and beta-thromboglobulin. MIPs affect a wide array of cell types and are important ... This family also includes platelet factor 4 and beta-thromboglobulin. MIPs affect a wide array of cell types and are important ... MIP-1 beta from rat recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested * pricing ... MIP-1 beta (CCL4) human recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested * pricing ...
CiNii 論文 -
Effects of Antihypertensive Treatment on Platelet Function in Essential...
Plasma beta-thromboglobulin to platelet factor 4 ratios as indices of vascular complications in essential hypertension GOMI T. ... Beta-thromboglobulin plasma levels in different stages of arterial hypertension PETRALITO A. ... Effects of prazosin on platelet aggregation and plasma beta-thromboglobulin in essential hypertension IKEDA T. ... The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4 DAWES J. ...
ELISA Kit1
- Should the Human Beta-Thromboglobulin (bTG) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement. (bioemm.com)
Protein9
- Beta-thromboglobulin (also known as β-thromboglobulin) is a protein that is stored in alpha-granules of platelets and released in large amounts after platelet activation. (wikipedia.org)
- beta-Thromboglobulin (betaTG) is a platelet specific protein present in the a-granules and secreted into the surrounding medium on cell activation. (iitkgp.ac.in)
- The data suggest that one or more high molecular weight (HMW) protein is released from alpha-granules and is broken down into smaller fragments after release to form beta-thromboglobulin (beta-TG)-like proteins by the action of metal-dependent proteases. (iitkgp.ac.in)
- It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP). (wikipedia.org)
- On je izoforma beta-tromboglobulina ili protrombocit bazični protein (PPBP). (wikipedia.org)
- 2) Secretion of proaggregatory mediators such as ADP, ATP, platelet factor 4 (PF4), beta thromboglobulin (beta-TG), thromboxane A 2 (TXA 2 ), fibrinogen and thrombospondin which are followed by the translocation of the alpha-granule membrane protein P-selectin (CD 62) to the platelet surface. (joplink.net)
- PF4 is a 70-amino acid (AA) platelet-specific protein that belongs to the CXC (or beta) chemokine subfamily, in which the first two of the four conserved cysteine residues are separated by one AA residue. (bloodjournal.org)
- In a comparison of indices of platelet activation (platelet factor 4 and beta-thromboglobulin) between depressed and nondepressed elderly subjects, the serotonin transporter protein and the serotonin transporter-linked promoter region are shared by platelets and brain neurons so that both central and peripheral effects would be expected. (psychological.com)
- α-defensin ( DEFA1 / DEFA3 ), pro-platelet basic protein ( PPBP ), and beta and alpha2 hemoglobin mRNA expression was significantly increased in H and CHD groups compared with controls, but only plasma PPBP and α-defensin proteins were correspondingly increased. (biomedcentral.com)
Platelets2
- We measured simultaneous plasma beta-thromboglobulin (BTG) and adhesion of 51Cr-labelled, washed platelets to confluent, bovine aortic endothelial monolayers in 50 insulin-dependent diabetic patients and 30 normal subjects (respective mean ages (+/- SD) = 45.1 +/- 16.4 and 45.8 +/- 17.2 years). (mysciencework.com)
- Platelet factor 4 , [beta]-thromboglobulin, and serotonin are specific products of platelets that are released on the activation of platelets (20). (thefreedictionary.com)
Proteins1
- Platelet activation can be estimated through flow cytometry, measurement of platelet-specific proteins such as beta-TG, PF4 and soluble P-selectin in plasma and TXA 2 metabolites in both plasma and urine dose-response and aggregometry [ 8 ]. (joplink.net)
Thromboxane A22
- In this patient we found a significant local pulmonary platelet activation and thrombin generation as indicated by the existence of a transpulmonary gradient for thromboxane A2, beta thromboglobulin and fibrinopeptide A. Prolonged heparin and acetylsalicylic acid treatment resulted in improvement of clinical and hemodynamic conditions. (nih.gov)
- Cigarette smoking increased the urinary excretion of 11-dehydro-thromboxane B2 (reflecting thromboxane A2 generation) and increased plasma concentration of the platelet alpha-granule constituents, platelet factor 4 and beta-thromboglobulin, compared with placebo treatment, indicating in vivo platelet activation. (nih.gov)
Megakaryocyte1
- Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. (wikipedia.org)
Measurement1
- Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders. (rush.edu)
Serum3
- Description: A sandwich quantitative ELISA assay kit for detection of Human Beta-Thromboglobulin (bTG) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. (bioemm.com)
- Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Beta-Thromboglobulin (bTG) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids. (bioemm.com)
- Blood was sampled before and after exercise to measure plasma and serum thromboxane B2 (TXB2), plasma beta-thromboglobulin (BTG), platelet count ratio (PCR), platelet count (PC), haemoglobin (Hb), haematocrit (Hct) and white cell count (WCC). (biomedsearch.com)
Substances1
- Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in [Alpha]-granules, platelet factor 4 , [Beta]-thromboglobulin, and platelet-derived growth factor. (thefreedictionary.com)
Levels9
- Levels of Beta-Thromboglobulin is used to index platelet activation. (wikipedia.org)
- Blood will be drawn via venopuncture for laboratory studies (WBPa, platelet factor 4, beta thromboglobulin and VWF antigen levels and activity). (utsouthwestern.edu)
- Spontaneous platelet aggregation in whole blood fell in the MaxEPA group (P less than 0.02) after 6 wk, but there were no changes in agonist-induced platelet aggregation, thromboxane generation in platelet-rich plasma, or plasma beta-thromboglobulin and platelet factor IV levels. (unboundmedicine.com)
- However, the beta-T levels of patients with MVP (n = 13, 52.9 +/- 25.5 ng/ml) did not differ from those of patients without MVP (n = 34, 55.7 +/- 33.7 ng/ml) significantly (p less than 0.4). (ahajournals.org)
- Since there was no significant difference between beta-TG levels of patients with and without MVP, the mitral-valve abnormality can not be the cause for the altered platelet activity. (ahajournals.org)
- Levels of platelet count, platelet-crit, mean platelet volume, spontaneous platelet aggregation, platelet factor 4 (PF4) and beta-thromboglobulin (beta-TG) were measured before operation and on the 1st, 3rd and 7th postoperative days. (cun.es)
- beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. (openaire.eu)
- Lung function and plasma levels of thromboxane B2, 6-ketoprostaglandin F1 alpha and beta-thromboglobulin in antigen-induced asthma before and after indomethacin pretreatment. (openaire.eu)
- Beta-thromboglobulin levels and oral contraception. (naver.com)
Willebrand2
- Several prothrombotic biomarkers, such as D-dimer, von Willebrand factor, and beta-thromboglobulin are present in higher concentrations in patients affected by atrial fibrillation (AF) [ 3 , 4 ]. (hindawi.com)
- After giving a short review of the literature the authors deal with the results of some more specific examinations (prostanoids, beta-thromboglobulin, the quantitative and qualitative analysis of Willebrand factor, etc.) which may give further data to the complex aetiopathogenesis of thrombotic microangiopathy. (elsevier.com)
Significantly higher1
- The mean plasma beta-thromboglobulin (beta-TG) level of the patients (mean = 54.9 +/- 31.4 ng/ml) was significantly higher than that of the controls (mean = 20.6 /- 6.9 ng/ml, p less than 0.001). (ahajournals.org)
Less than 0.011
- After the operation there was a significant and progressive increase (p less than 0.01) in PF4 and beta-TG, and the presence of circulating platelet aggregates was demonstrated. (cun.es)
Factors1
- Exemplary members of the family include the colony-stimulating factors (GM-CSF, M-CSF, G-CSF, interleukin-3), the interleukins (IL-1, IL-2, IL-11), the interferons (alpha, beta and gamma), the tumor necrosis factors (alpha and beta) and erythropoietin. (google.com)
Human2
- Characterization of the human beta-thromboglobulin gene. (wikipedia.org)
- Fresh heparinized human blood was pooled, divided between the two systems and circulated for 24 h at 37 degrees C. Platelet count, plasma concentration of betathromboglobulin (BTG), platelet membrane density of glycoprotein (GP) Ib and of GPIIb/IIIa were assayed before the start and at 0.5, 1, 3, 12 and 24 h of perfusion. (gu.se)
Concentrations1
- The significantly elevated plasma beta-TG concentrations in the patient's group indicate an increased platelet activity in vivo. (ahajournals.org)
Antithrombin1
- Thrombin antithrombin-III complex (TAT), beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) were used as coagulation activation markers. (uni-wuerzburg.de)
Release4
- The release of granular content (β-thromboglobulin and platelet factor 4) to the circulation in response to epinephrine was not significant. (ahajournals.org)
- Levine et al found that mental stress provoked a rise in platelet release of platelet factor 4 and beta thromboglobulin [6]. (springer.com)
- These changes correlated with modifications in platelet morphology (decrease in swirling), leakage of lactate dehydrogenase, and release of beta‐thromboglobulin. (deepdyve.com)
- Synergistic potentiation of 5-hydroxytryptamine secretion by platelet agonists and phorbol myristate acetate despite inhibition of agonist-induced arachidonate/thromboxane and beta-thromboglobulin release and Ca2+ mobilization by phorbol myristate acetate. (openaire.eu)
Aggregation1
- Platelet aggregation measured by adenosine 5'-diphosphate- or adrenaline-induced aggregation, platelet factor-4 or beta-thromboglobulin did not differ between patients and controls. (nih.gov)
Inhibition1
- The sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of platelet releasate after inhibition of metalloproteinases with ethyleneglycol-bis-(beta-aminoethyl ether)N,N'-tetra acetic acid (EGTA) showed disappearance of an 8.0-kDa band. (iitkgp.ac.in)
Factor3
- This family also includes platelet factor 4 and beta-thromboglobulin. (sigmaaldrich.com)
- We measured the platelet counts, platelet factor 4 (PF4), β-thromboglobulin (β-TG), and CD41 and CD42b platelet surface markers at 30, 120, and 240 min. (springer.com)
- PF4 (platelet factor 4) and BTG (beta - thromboglobulin) were determined in plasma from the umbilical artery.Results: The concentration of PF4 was higher in male newborns (89.55 IU/ml) than in female newborns (77.22 IU/ml). (medscimonit.com)
Patients2
- Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus. (mysciencework.com)
- During exercise beta-thromboglobulin decreased significantly in both OSA patients and controls. (nih.gov)
Effect1
- Effect of angiotensin converting enzyme inhibitors and beta-blockers on left ventricular remodeling after coronary artery bypass graft surgery. (nih.gov)